|
We live amid the long-term risk of novel coronavirus (COVID-19), and need to find any new approaches to conquer globe COVID-19 epidemics including any effective vaccines, precise sensing tools, ultraviolet C wavelength (UVC) disinfection technologies. Up-to-date, it is still elusive to acquire point-of-care clinical diagnosis tools or personalized nanophotonic sensors for tracing end-expiration COVID-19, due to the principle limit of evanescent-field sensing technologies and detection sensitivities among nano- to pico-molar, despite dual-functional plasmonic photothermal biosensors for highly accurate severe acute respiratory syndrome coronavirus 2 detection with the limit of 0.22 pico-molar within several minutes in air is recently published in ACS Nano., antibodies, DNA strands or enzymes to capture and detect a COVID-19 target molecule, or analyte in a sample are widely applied. Miniaturizing everything, automating it, simplifying it and making it clinically reliable is the final goal of developing the next generation of approaches to drive personalized precision medicine. To meet these demands, atto-level nanobiophotonic sensing approach using silicon technology beyond evanescent-field principle limits is postulated herein. This approach is based on quantum-field principle, wherein single biophoton donors and acceptors are self-assembled by photoluminescent nanomedicine crystals on silicon substrates. The design of novel diagnostics based on nanobiophotonic sensing approach using silicon technology based on quantum-field principle is opening new avenues for personalized medicine, optical label-free biosensing, directly real-time analyzing biomolecular interactions, further exploiting biomedical applications, boosting the development of precise and individualized therapies for COVID-19 infection etc. worldwide serious diseases and facilitating the widespread administration of such personalized approaches.
|
